Exiqon Licenses LNA Technology to Becton Dickinson | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exiqon today announced it has granted a non-exclusive license for its locked nucleic acids technology to Becton Dickinson for the development of diagnostics for infectious diseases.

Under the terms of the deal, Exiqon will receive upfront and milestone payments and royalties on global sales of products stemming from the agreement. No other financial terms were disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.